<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109676</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/21/0490</org_study_id>
    <nct_id>NCT05109676</nct_id>
  </id_info>
  <brief_title>Monitoring of Progesterone Administered in Infertile Patients During a Cycle of Frozen Embryo Transfer.</brief_title>
  <acronym>PEKAPROGE</acronym>
  <official_title>Monitoring of Progesterone Administered in Infertile Patients During a Cycle of Frozen Embryo Transfer: a Population Pharmacokinetic Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During an In Vitro Fertilization (IVF) attempt, several embryos are obtained but not all of&#xD;
      them can be transferred to the uterus in the same cycle due to the risk of multiple&#xD;
      pregnancies. Thus, it is very common for these couples to benefit from cryopreservation.&#xD;
      Patients scheduled for frozen embryo transfer (TEC) receive estrogen and progesterone&#xD;
      replacement therapy to prepare the endometrium for implantation. Data from the literature&#xD;
      recently showed that low progesterone on the day of embryo transfer was responsible for a&#xD;
      significantly higher rate of implantation failure and miscarriage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average plasma progesterone concentration.</measure>
    <time_frame>Day of embryo transfer.</time_frame>
    <description>Dosage of apparent clearance (CL/F)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>Patients having embryo transfert</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients benefit from the usual treatment for frozen embryo transfer with a preparatory cycle of the artificial endometrium: 150 Âµg of percutaneous estradiol for approximately 11 days and 200 mg of progesterone morning and evening to be taken vaginally for 2 days in case of embryo transfer at day 2 stage, 3 days in case of embryo transfer at day 3 stage, 5 days in case of day 5 embryo transfer or 6 days in case of day 6 embryo transfer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>A questionnaire will be offered to patients and identify the schedules of administration of progesterone, the day and time of blood samples taken as part of the care, the potential adverse events associated with this administration.</description>
    <arm_group_label>Patients having embryo transfert</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient undergoing a frozen embryo transfer in an artificial cycle at the AMP&#xD;
             center of the Toulouse University Hospital.&#xD;
&#xD;
          -  Affiliation to a social security scheme or equivalent&#xD;
&#xD;
          -  Patient fulfilling the conditions for access to the AMP according to French bioethics&#xD;
             law&#xD;
&#xD;
          -  Patient having given her consent (oral or written) after clear and fair information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who received intramuscular administration of progesterone during the&#xD;
             endometrial preparation phase.&#xD;
&#xD;
          -  Patient with comprehension difficulties.&#xD;
&#xD;
          -  Protected adult patient (safeguard of justice, guardianship or curatorship)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Gatimel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Gatimel, MD</last_name>
    <phone>5 67 77 10 08</phone>
    <phone_ext>+33</phone_ext>
    <email>gatimel.n@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas Gatimel</last_name>
      <phone>0567771008</phone>
      <email>gatimel.n@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Gatimel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

